As prominent groups in U.S. health care ramp up use of cost-effectiveness analysis to measure and communicate the value of new drugs and other interventions, an expert panel has released updated guidelines for such analysis.
No takes yet. Share an insight, caveat, or question.
Neumann et al. (2017) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: